Teva Pharmaceutical Industries Ltd. announced the early tender results in connection with its previously announced tender offers (the Offers) and that it is increasing the combined aggregate purchase price (exclusive of accrued and unpaid interest) (the Total Maximum Amount) from $3,500,000,000 to $4,000,000,000 for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: 1.250% Senior Notes due 2023, ISIN XS1211040917, issued by Teva Pharmaceutical Finance Netherlands II B.V. (the Priority 1 Notes); 2.800% Senior Notes due 2023, CUSIP 88167A AD3 /ISIN US88167AAD37, issued by Teva Pharmaceutical Finance Netherlands III B.V. (the Priority 2 Notes); 3.250% Senior Notes due 2022, ISIN XS1812903828 (Registered), ISIN XS1789747265 (144A), ISIN XS1789745137 (RegS), issued by Teva Pharmaceutical Finance Netherlands II B.V. (the Priority 3 Notes); 2.950% Senior Notes due 2022, CUSIP 88165F AG7 /ISIN US88165FAG72, issued by Teva Pharmaceutical Finance Company B.V. (the Priority 4 Notes, and together with the Priority 1 Notes, the Priority 2 Notes and the Priority 3 Notes, the Pool 1 Notes); 1.125% Senior Notes due 2024, ISIN XS1439749281, issued by Teva Pharmaceutical Finance Netherlands II B.V. (the Priority 5 Notes); and 6.000% Senior Notes due 2024, CUSIP 88167A AL5 /ISIN US88167AAL52 (Registered), CUSIP 88167A AH4 /ISIN US88167AAH41 (144A), ISIN USN8540WAA29 (RegS), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the Priority 6 Notes, and together with the Priority 5 Notes, the Pool 2 Notes, and together with the Pool 1 Notes, the Notes). In addition, Teva has exercised its discretion to increase the tender cap for the Pool 1 Notes from $2,500,000,000 (equivalent) to $2,996,000,000 (equivalent) (the ?Pool 1 Tender Cap?) and the tender cap for the Pool 2 Notes from $900,000,000 (equivalent) to $1,013,000,000 (equivalent) (the ?Pool 2 Tender Cap? and, together with the Pool 1 Tender Cap, the Tender Caps) Except as provided above, the terms and conditions of the Offers remain unchanged. Teva is engaging in the Offers to proactively manage and extend the maturity profile of its debt. Teva expects to fund the Offers with the proceeds from the registered public offering of Teva Pharmaceutical Finance Netherlands II B.V. and Teva Pharmaceutical Finance Netherlands III B.V. of debt securities that commenced concurrently with the Offers and closed on November 9, 2021, with gross proceeds sufficient to fund the Total Consideration for Notes to be purchased pursuant to the Offers. The respective principal amounts of all series of Notes that were validly tendered and not validly withdrawn at or prior to 5:00 p.m., Eastern Time, on Tuesday, November 9, 2021 (the Early Tender Time) are specified in the table below. Holders who validly tendered and did not validly withdraw Notes at or prior to the Early Tender Time and whose Notes are accepted for purchase pursuant to the Offers will receive the applicable Total Consideration, which includes an early tender premium of $30.00 per $1,000 or ?30.00 per ?1,000, as applicable, principal amount of the Notes accepted for purchase pursuant to the Offers (the Early Tender Premium).